Recent advances in NSCLC with established alterations are summarized, including EGFR, ALK, ROS1, KRAS, BRAF, RET, HER2, MET, and NTRK, and emerging targets are discussed, and emerging targets, such as NRG1 fusions, MTAP loss, and SMARCA4 deficiency are discussed.
L. Hendriks, Jessica J. Lin, D. S. Tan et al.· The Lancet Respiratory Medic...· 2 citations
A deeper understanding of the brain metastatic ecosystem may enable the development of more effective, biology-driven therapeutic approaches for NSCLC BM.
Marcel Kemper, Lea Reitnauer, A. Leonetti et al.· Cancer Biome and Targeted Th...· 0 citations
By combining structured clinical variables and multimodal imaging data, the AI-HOPE Lung Cancer study aims to support refined risk stratification and treatment personalization, ultimately facilitating the responsible integration of AI into routine thoracic oncology practice.
F. Ogliari, M. Ferrara, J. Huijs et al.· ESMO real world data and dig...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.